同: cefepime

同: cefepime

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2022/11/30 11:37:24」(JST)

wiki en

Cefepime is a fourth-generation cephalosporin antibiotic. Cefepime has an extended spectrum of activity against Gram-positive and Gram-negative bacteria, with greater activity against both types of organism than third-generation agents. A 2007 meta-analysis suggested when data of trials were combined, mortality was increased in people treated with cefepime compared with other β-lactam antibiotics.^[1] In response, the U.S. Food and Drug Administration (FDA) performed their own meta-analysis which found no mortality difference.^[2]

Cefepime was patented in 1982 by Bristol-Myers Squibb and approved for medical use in 1994.^[3] It is available as a generic drug and sold under a variety of trade names worldwide.^{[citation needed]}

It was removed from the World Health Organization's List of Essential Medicines in 2019.^[4]

Medical use

Cefepime is usually reserved to treat moderate to severe nosocomial pneumonia, infections caused by multiple drug-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.^[5]

Cefepime has good activity against important pathogens including Pseudomonas aeruginosa, Staphylococcus aureus, and multiple drug-resistant Streptococcus pneumoniae. A particular strength is its activity against Enterobacteriaceae. Whereas other cephalosporins are degraded by many plasmid- and chromosome-mediated beta-lactamases, cefepime is stable and is a front-line agent when infection with Enterobacteriaceae is known or suspected.^{[medical citation needed]}

Spectrum of bacterial susceptibility

Cefepime is a broad-spectrum cephalosporin antibiotic and has been used to treat bacteria responsible for causing pneumonia and infections of the skin and urinary tract. Some of these bacteria include Pseudomonas, Escherichia, and Streptococcus species. The following represents MIC susceptibility data for a few medically significant microorganisms:^[6]

Escherichia coli: ≤0.007 – 128 μg/ml
Pseudomonas aeruginosa: 0.06 – >256 μg/ml
Streptococcus pneumoniae: ≤0.007 – >8 μg/ml

Chemistry

The combination of the syn-configuration of the methoxy imino moiety and the aminothiazole moiety confers extra stability to β-lactamase enzymes produced by many bacteria. The N-methyl pyrrolidine moiety increases penetration into Gram-negative bacteria. These factors increase the activity of cefepime against otherwise resistant organisms including Pseudomonas aeruginosa and Staphylococcus aureus.

Trade names

Following expiration of the Bristol-Myers Squibb patent,^[when?] cefepime became available as a generic and is now^[when?] marketed by numerous companies worldwide under tradenames including Neopime (Neomed), Maxipime, Cepimax, Cepimex, and Axepim.

References

^ Yahav D, Paul M, Fraser A, Sarid N, Leibovici L (2007). "Efficacy and safety of cefepime: a systematic review and meta-analysis". Lancet Infect Dis. 7 (5): 338–48. doi:10.1016/S1473-3099(07)70109-3. PMID 17448937.
^ "Information for Healthcare Professionals: Cefepime (marketed as Maxipime)". Food and Drug Administration. Archived from the original on 2 November 2017. Retrieved 2 August 2009.
^ Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495. Archived from the original on 19 June 2021. Retrieved 19 September 2020.
^ World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.
^ Chapman TM, Perry CM (2003). "Cefepime: a review of its use in the management of hospitalized patients with pneumonia". Am J Respir Med. 2 (1): 75–107. doi:10.1007/bf03256641. PMID 14720024.
^ http://www.toku-e.com/Assets/MIC/Cefepime.pdf Archived 1 November 2018 at the Wayback Machine^{[bare URL PDF]}

External links

"Cefepime". Drug Information Portal. U.S. National Library of Medicine.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 嚢胞性線維腺症：呼吸器症状が急性増悪した場合の治療 cystic fibrosis treatment of acute pulmonary exacerbations
2. 頭蓋内硬膜外膿瘍 intracranial epidural abscess
3. 成人における確定診断を得られていない低血圧やショックの評価および初期アプローチ evaluation of and initial approach to the adult patient with undifferentiated hypotension and shock
4. セフェム系 cephalosporins
5. 基質特異性拡張型β-ラクタマーゼ extended spectrum beta lactamases

English Journal

Prevalence of antimicrobial resistance of non-typhoidal Salmonella serovars in retail aquaculture products.

Zhang J1, Yang X2, Kuang D2, Shi X2, Xiao W3, Zhang J4, Gu Z5, Xu X6, Meng J7.
International journal of food microbiology.Int J Food Microbiol.2015 Oct 1;210:47-52. doi: 10.1016/j.ijfoodmicro.2015.04.019. Epub 2015 Apr 16.
Aquaculture products can become sources of Salmonella by exposure to contaminated water or through processing practices, thus representing a public health hazard. A study was conducted on Salmonella contamination in aquaculture products sampled from marketplaces and retailers in Shanghai, China. A t
PMID 26093990

Hypersensitivity Pneumonitis Caused by Cephalosporins With Identical R1 Side Chains.

Lee SH1, Kim MH1, Lee K1, Jo EJ1, Park HK2.
Allergy, asthma & immunology research.Allergy Asthma Immunol Res.2015 Sep;7(5):518-22. doi: 10.4168/aair.2015.7.5.518. Epub 2014 Nov 25.
Drug-induced hypersensitivity pneumonitis results from interactions between pharmacologic agents and the human immune system. We describe a 54-year-old man with hypersensitivity pneumonitis caused by cephalosporins with identical R1 side chains. The patient, who complained of cough with sputum, was
PMID 25749765

In Vitro Activities of 21 Antimicrobial Agents Alone and in Combination with Aminoglycosides or Fluoroquinolones against Extended-Spectrum-β-Lactamase-Producing Escherichia coli Isolates Causing Bacteremia.

Cha MK1, Kang CI2, Kim SH3, Cho SY4, Ha YE4, Wi YM5, Chung DR3, Peck KR4, Song JH3; Korean Network for Study on Infectious Diseases (KONSID).
Antimicrobial agents and chemotherapy.Antimicrob Agents Chemother.2015 Sep;59(9):5834-7. doi: 10.1128/AAC.01121-15. Epub 2015 Jun 29.
We evaluated the in vitro activity of various antimicrobials alone and in combination against 291 extended-spectrum-β-lactamase-producing Escherichia coli (ESBL-EC) isolates causing bacteremia in South Korean hospitals. Ceftazidime, cefepime, and piperacillin-tazobactam in combination with amikacin
PMID 26124174

Japanese Journal

Usefulness of the Final Filter of the IV Infusion Set in Intravenous Administration of Drugs : Contamination of Injection Preparations by Insoluble Microparticles and Its Causes

倉本敬二,東林海徹,仲川善人
藥學雜誌 126(4), 289-295, 2006-04-01
… The test drugs used were Doyle^[○!R] 1g vial, Cefotax^[○!R] 1g vial, Minomycin^[○!R] 100mg vial, Omegacin^[○!R] 0.3g vial, Maxipime^[○!R] 1g vial, Rocephin^[○!R] 1g vial, Isovorin^[○!R] 25mg vial, Diamox^[○!R] 500mg vial and Fungizone^[○!R] 50mg vial. …
NAID 110006154936

他剤無効例に対するcefepimeの臨床効果に関する市販後特別調査

斎藤厚,大塚真奈美,小林一雄,大坪一之
日本化学療法学会雜誌 = Japanese journal of chemotherapy 50(1), 29-46, 2002-01-25
細菌感染症に対するβ-lactam系薬による治療無効例の要因の主なものとして起炎菌が産生するβ-lactamaseによるものが考えられる。Cefepime (CFPM, 注射用マキシピーム <SUB>®</SUB>) はこのβ-lactamaseにきわめて安定であるので, β-lactam系薬治療無効例に対しても高い臨床効果が期待できることから, 今回特別調査を実施した。全 …
NAID 10008028843

Related Pictures

Maxipime™ (Cefepime for Injection, USP) MAXİPİME 0,5 GR 1 FLAKON prospektüs Hospital Thailand - Maxipime 1g Injection MAXIPIME (Elan Pharmaceuticals, Inc.): FDA Maxipime - drug review: dosage, side Maxipime Dosage & Drug Information | MIMS

★リンクテーブル★

関連記事	「Maxipime」

「Maxipime」

Cefepime
Clinical data
Pronunciation	/ˈsɛfɪpiːm/ or /ˈkɛfɪpiːm/
Trade names	Maxipime, Voco
AHFS/Drugs.com	Monograph
MedlinePlus	a698021
Pregnancy; category	AU: B1; ;
Routes of; administration	Intravenous, intramuscular
ATC code	J01DE01 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only) ; CA: ℞-only ; UK: POM (Prescription only) ; US: ℞-only ;
Pharmacokinetic data
Bioavailability	100% (IM)
Metabolism	Hepatic 15%
Elimination half-life	2 hours
Excretion	Renal 70–99%
Identifiers
	IUPAC name (6R,7R,Z)-; 7-(2-(2-aminothiazol-4-yl)-2-(methoxyimino)acetamido)-; 3-((1-methylpyrrolidinium-1-yl)methyl)-8-oxo-5-thia-; 1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylate;
CAS Number	88040-23-7 ;
PubChem CID	5479537;
DrugBank	DB01413 ;
ChemSpider	4586395 ;
UNII	807PW4VQE3;
KEGG	D02376 ;
ChEBI	CHEBI:478164 ;
ChEMBL	ChEMBL186 ;
CompTox Dashboard (EPA)	DTXSID70873208 ;
ECHA InfoCard	100.171.025
Chemical and physical data
Formula	C19H24N6O5S2
Molar mass	480.56 g·mol−1
3D model (JSmol)	Interactive image;
Melting point	150 °C (302 °F) (dec.)
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=N\OC)/c3nc(sc3)N)C[N+]4(C)CCCC4)C([O-])=O;
	InChI InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1 ; Key:HVFLCNVBZFFHBT-ZKDACBOMSA-N ;
	(verify)

　　[★] セフェピム。マキシピーム

[pmid17448937-1] Yahav D, Paul M, Fraser A, Sarid N, Leibovici L (2007). "Efficacy and safety of cefepime: a systematic review and meta-analysis". Lancet Infect Dis. 7 (5): 338–48. doi:10.1016/S1473-3099(07)70109-3. PMID 17448937.

[2] "Information for Healthcare Professionals: Cefepime (marketed as Maxipime)". Food and Drug Administration. Archived from the original on 2 November 2017. Retrieved 2 August 2009.

[Fis2006-3] Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495. Archived from the original on 19 June 2021. Retrieved 19 September 2020.

[WHO21st-4] World Health Organization (2019). Executive summary: the selection and use of essential medicines 2019: report of the 22nd WHO Expert Committee on the selection and use of essential medicines. Geneva: World Health Organization. hdl:10665/325773. WHO/MVP/EMP/IAU/2019.05. License: CC BY-NC-SA 3.0 IGO.

[pmid14720024-5] Chapman TM, Perry CM (2003). "Cefepime: a review of its use in the management of hospitalized patients with pneumonia". Am J Respir Med. 2 (1): 75–107. doi:10.1007/bf03256641. PMID 14720024.

[6] ttp://www.toku-e.com/Assets/MIC/Cefepime.pdf Archived 1 November 2018 at the Wayback Machine^{[bare URL PDF]}

匿名

検索

案内

案内

maxipime